The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with tra...

Descripción completa

Detalles Bibliográficos
Autores: Jiménez Fonseca, Paula|||0000-0003-4592-3813, Foy, Victoria, Raby, Sophie, Carmona-Bayonas, Alberto|||0000-0002-1930-9660, Macía-Rivas, Lola, Arrazubi, Virginia, Cacho Lavín, Diego, Hernandez San Gil, Raquel, Custodio, Ana, Cano, Juana María|||0000-0002-2493-0988, Fernández Montes, Ana|||0000-0003-4630-5830, Mirallas, Oriol|||0000-0002-8492-5195, Macias Declara, Ismael, Vidal Tocino, Rosario|||0000-0002-0588-2001, Visa, Laura|||0000-0002-3409-8857, Limón, María Luisa|||0000-0003-4409-3029, Pimentel, Paola|||0000-0002-1676-5724, Martínez Lago, Nieves|||0000-0002-0408-6871, Saurí Nadal, Tamara|||0000-0002-7479-5120, Martín-Richard, Marta|||0000-0003-4933-2463, Mangas, Monserrat, Gil Raga, Mireia|||0000-0002-4508-7395, Calvo, Aitana|||0000-0002-7470-8517, Reguera, Pablo|||0000-0002-0847-5719, Granja, Mónica, Martín Carnicero, Alfonso|||0000-0002-8564-2875, Hernández Pérez, Carolina, Cerdà, Paula|||0000-0003-0101-188X, Gomez Gonzalez, Lucía, Garcia Navalon, Francisco, Pacheco-Barcia, Vilma|||0000-0003-0141-1306, Gutierrez Abad, David, Ruiz Martín, Maribel, Weaver, Jamie, Mansoor, Wasat|||0000-0002-1477-4934, Gallego Plazas, Javier|||0000-0002-0584-1242
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:303841
Acceso en línea:https://ddd.uab.cat/record/303841
https://dx.doi.org/urn:doi:10.1177/17588359231157641
Access Level:acceso abierto
Palabra clave:HER2-positive
Gastric cancer
Nomogram
Oesophageal cancer
Survival
Trastuzumab
Descripción
Sumario:Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab. Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included. The model was externally validated in an independent series (The Christie NHS Foundation Trust, Manchester, UK). In all, 737 patients were recruited (AGAMENON-SEOM, n = 654; Manchester, n = 83). Median PFS and OS in the training cohort were 7.76 [95% confidence interval (CI), 7.13-8.25] and 14.0 months (95% CI, 13.0-14.9), respectively. Six covariates were significantly associated with OS: neutrophil-to-lymphocyte ratio, Eastern Cooperative Oncology Group performance status, Lauren subtype, HER2 expression, histological grade and tumour burden. The AGAMENON-HER2 model demonstrated adequate calibration and fair discriminatory ability with a c-index for corrected PFS/OS of 0.606 (95% CI, 0.578-0.636) and 0.623 (95% CI, 0.594-0.655), respectively. In the validation cohort, the model is well calibrated, with a c-index of 0.650 and 0.683 for PFS and OS, respectively. The AGAMENON-HER2 prognostic tool stratifies HER2-positive AGA patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints.

Similares en LA Referencia